相关实验视频
Updated: Jul 25, 2025

Surgical Models of Gastroesophageal Reflux with Mice
Published on: August 25, 2015
基于药物遗传学的方法来管理胃食道逆流性疾病:当前的前景和未来的步骤
Eda Eken1,2, David S Estores3, Emily J Cicali1,2
1Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.
在CYP2C19的遗传变异显著影响质子抑制剂 (PPI) 对GERD的有效性. 基因型导向的PPI剂量可能会改善胃食道逆流性疾病 (GERD) 患者的治疗结果.
科学领域:
- 药物基因组学 药物基因组学
- 胃肠病学 胃肠病学
背景情况:
- 质子抑制剂 (PPI) 是治疗诸如GERD等酸性疾病的首要疗法.
- CYP2C19的遗传变异影响PPI代谢和患者的反应.
- 目前的指导方针不建议对PPI处方进行CYP2C19基因定型.
研究的目的:
- 审查支持CYP2C19基因型引导PPI剂量用于GERD的证据.
- 探索精准医学策略,以优化GERD管理.
主要方法:
- 关于CYP2C19,PPI药理动力学和临床结果的文献综述.
- 分析现有的药物遗传指南和最近的研究数据.
主要成果:
- 强有力的证据将CYP2C19的遗传变异与PPI药理动力学和临床结果联系起来.
- 最近的数据表明,基因型导向的PPI剂量对GERD患者有潜在的益处.
结论:
- CYP2C19基因型定制可能会增强对GERD的PPI治疗.
- 精准医学方法,包括基因型导向剂量,为GERD管理提供未来的方向.
相关概念视频
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Gastroesophageal Reflux Disease I: Meaning and Pathophysiology
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

